Cost-of-illness studies of atrial fibrillation: Methodological considerations

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 5, 2014, Pages 661-684

  Becker, Christian ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

atrial fibrillation; cost of illness; decision support technique; health economics; review

Indexed keywords

CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DISEASE REGISTRY; DISEASE SURVEILLANCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MEDICARE; POPULATION RESEARCH; PRIMARY MEDICAL CARE; REVIEW; STRATEGIC PLANNING; SYSTEMATIC REVIEW; ATRIAL FIBRILLATION; ECONOMICS; HEALTH INSURANCE; HOSPITAL COST; PRIMARY HEALTH CARE; STATISTICAL MODEL; STROKE; TIME; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; INSURANCE, HEALTH; MODELS, ECONOMIC; PRIMARY HEALTH CARE; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907060272     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.940904     Document Type: Review

References (60)

1. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U. S. adult population. Am J Cardiol 2013; 112(8):1142-7
2. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34(35):2746-51
3. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012;142(6): 1489-98
4. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014;129(8): 837-47
5. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: An analysis based on 8.3 million patients. Europace 2013;15(4): 486-93
6. Heeringa J, Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27(8): 949-53
7. Leong DP, Eikelboom JW, Healey JS, Connolly SJ. Atrial fibrillation is associated with increased mortality: causation or association? Eur Heart J 2013;34(14): 1027-30
8. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991;22(8):983-8
9. Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: A 15-year study of all hospitalizations in Australia. Arch Intern Med 2012;172(9):739-41
10. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study. Circulation 2004;110(9):1042-6
11. Larg A, Moss JR. Cost-of-illness studies: A guide to critical evaluation. Pharmcoeconomics 2011;29(8):653-71
12. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies : A review of current methods. Pharmacoeconomics 2006;24(9): 869-90
13. Clabaugh G, Ward MM. Cost-of-illness studies in the United States: A systematic review of methodologies used for direct cost. Value Health 2008;11(1):13-21
14. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77(1):51-63
15. Molinier L, Bauvin E, Combescure C, et al. Methodological considerations in cost of prostate cancer studies: A systematic review. Value Health 2008;11(5):878-85
16. Drummond M, Drummond M. Methods for the economic evaluation of health care programmes. Oxford University Press; Oxford, New York, NY, USA: 2005
17. O'Ceilleachair A, Hanly P, Skally M, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. Med Care 2013;51(4):339-50
18. O'Reilly DJ, Hopkins RB, Healey JS, et al. The burden of atrial fibrillation on the hospital sector in Canada. Can J Cardiol 2013;29(2):229-35
19. Keech M, Punekar YS, Choy AM. Trends in atrial fibrillation hospitalisation in Scotland: An increasing cost burden. Br J Cardiol 2012;19(4):173-7
20. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart 2004;90(3):286-92
21. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9(5):348-56
22. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ 2011;12(5):479-87
23. Amin AN, Jhaveri M, Lin J. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther 2011; 28(10):907-26
24. Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: A Medicare perspective. J Med Econ 2008;11(2):281-98
25. Pelletier E, Hernandez J, Clark M, et al. Medicare costs and health resource utilisation associated with atrial fibrillation in the elderly. J Med Econom 2005;8(1-4): 55-65
26. Reinhold T, Lindig C, Willich SN, Bruggenjurgen B. The costs of atrial fibrillation in patients with cardiovascular comorbidities - a longitudinal analysis of German health insurance data. Europace 2011;13(9):1275-80
27. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4(3):313-20
28. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005; 21(10):1693-9
29. Rohrbacker NJ, Kleinman NL, White SA, et al. The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: Associated costs, absences, and objective productivity loss. J Occup Environ Med 2010;52(4):383-91
30. Boccuzzi SJ, Martin J, Stephenson J, et al. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Curr Med Res Opin 2009;25(12): 2853-64
31. Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26(9): 847-57
32. Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy 2009; 29(12):1417-26
33. Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc 2013; 2(6):e000479
34. Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J 2012;164(6):918-24
35. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18(6): 628-33
36. Ghatnekar O, Glader EL. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: A 3-year analysis of registry incidence data from 2001. Value Health 2008;11(5):862-8
37. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147(1):121-6
38. McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2009; 12(2):293-301
39. Reinhold T, Rosenfeld S, Muller-Riemenschneider F, et al. [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs]. Herz 2012;37(5):534-42
40. Jonsson L, Eliasson A, Kindblom J, et al. Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. Appl Health Econ Health Policy 2010;8(5): 317-25
41. Scheuringer M, Sahakyan N, Krobot KJ, Ulrich V. Cost of clinical events in health economic evaluations in Germany: A systematic review. Cost Eff Resour Alloc 2012;10(1):7
42. Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007;10(2):137-43
43. Rostagno C, La Meir M, Gelsomino S, et al. Atrial fibrillation after cardiac surgery: incidence, risk factors, and economic burden. J Cardiothorac Vasc Anesth 2010; 24(6):952-8
44. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008; 10(4):403-11
45. Holstenson E, Ringborg A, Lindgren P, et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace 2011;13(1):23-30
46. Bruggenjurgen B, Reinhold T, McBride D, Willich SN. [Atrial fibrillation- epidemiologic, economic and individual burden of disease]. Dtsch Med Wochenschr 2010;135(Suppl 2):S21-5
47. Kassianos G, Arden C, Hogan S, et al. The non-anticoagulation costs of atrial fibrillation management: findings from an observational study in NHS Primary Care. Drugs Context 2014;2014:212254
48. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000;320(7245):1335
49. Murin J, Naditch-Brule L, Brette S, et al. Clinical characteristics, management, and control of permanent vs nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One 2014;9(1): e86443
50. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007;10(5): 336-47
51. Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law 2008; 33(2):225-47
52. Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ. A cross-national perspective on cost of illness: A comparison of studies from The Netherlands, Australia, Canada, Germany, United Kingdom, and Sweden. Eur J Health Econ 2005;6(3): 223-32
53. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22(13):857-76
54. Danzon PM, Wilensky GR, Means KE. Alternative strategies for Medicare payment of outpatient prescription drugs - Part B and beyond. Am J Manag Care 2005;11(3): 173-80
55. Krauth C, Hessel F, Hansmeier T, et al. Empirische Bewertungssatze in der gesundheitsokonomischen Evaluation - ein Vorschlag der AG Methoden der gesundheitsokonomischen Evaluation (AG MEG). Gesundheitswesen 2005;67(10): 736-46
56. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002; 20(7):443-54
57. Costa N, Derumeaux H, Rapp T, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2012;2(1):18
58. Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health 2012;15(2):240-8
59. Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: A systematic review of the recent literature. Europace 2011;13(10): 1375-85
60. Larsen TB, Lip GY. Warfarin or novel oral anticoagulants for atrial fibrillation? Lancet 2014;383(9921):931-3